ReviewFrontiers in neuroscience2026
The potential role of aberrant microglial synaptic pruning in the neurodevelopmental pathogenesis of tourette syndrome.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tourette syndrome is a neurodevelopmental disorder traditionally attributed to dopamine system hyperactivity within the cortico-striato-thalamo-cortical circuitry. However, classical neurotransmitter hypotheses fail to fully explain the spatiotemporal and developmental specificities of the disorder. Consequently, research focus has shifted toward the neuroimmune microenvironment, specifically the role of microglia. This review aims to comprehensively explore the potential mechanisms of microglia-mediated aberrant synaptic pruning in the pathogenesis of tourette syndrome and to evaluate emerging therapeutic strategies. Methodologically, the study employs a narrative review approach to synthesize current neuroimmunobiology literature to reconstruct the pathological trajectory from early immune dysregulation to targeted interneuron impairment. Additionally, it conceptually explores natural product active monomers through a multi-target network pharmacology framework and assesses the translational potential of engineered nanodelivery systems. The findings indicate that genetic susceptibilities, such as histidine decarboxylase gene mutations, interact with environmental stressors, like maternal immune activation, to induce a chronically primed state in basal ganglia microglia. These primed innate immune cells are hypothesized to execute excessive synaptic pruning against highly vulnerable parvalbumin-expressing fast-spiking interneurons, a process significantly facilitated by the pathological downregulation of presynaptic protective signals. The physical loss of this local gamma-aminobutyric acid-ergic inhibitory network attenuates feedforward inhibition on medium spiny neurons, potentially contributing to macroscopic dopaminergic disinhibition. To address these mechanisms, multi-target natural therapies delivered via intelligent nanoplatforms present a theoretically promising approach to penetrate the blood-brain barrier and reverse pathological microglial phenotypes. Ultimately, this manuscript proposes a perspective of tourette syndrome as a microstructural developmental disorder of the circuitry rather than a mere neurotransmitter imbalance, providing a critical theoretical foundation for developing precise, next-generation neuroimmune-modulating interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.